American Shared Hospital Services (AMS) Earnings Call Transcript & Summary

April 4, 2025

NYSE American US Health Care Health Care Providers and Services earnings 25 min

Earnings Call Speaker Segments

Kirin Smith

executive
#1

Thanks, Betsy, and I appreciate all of you being with us today. The press release covering AMS' results for the fourth quarter and the whole of 2024 came out this morning ahead of the market opening. Should you require one, you'll find it on the company's site, www.ashs.com, listed under Press Releases within the Investors tab. Ahead of handing things to management, I want to offer a few comments regarding forward-looking statements. Be aware that any remarks given during this call regarding future expectations, plans and prospects for the company count as forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from what those forward-looking statements suggest, owing to a number of important factors, among them those covered in the company's SEC filings. That includes the quarterly report on Form 10-Q covering the 3-month period that ended September 30, 2024, the annual report on Form 10-K covering the year that ended December 31, 2023, and the definitive proxy statement for the Annual Meeting of Shareholders held on June 25, 2024. No obligation is assumed by the company to update any information in this conference call. Prior to handing the call to Ray, I want to remind everybody about our Q&A policy, under which every participant gets time for one question plus one follow-up. As ever, we'll gladly take further questions off-line whenever you like. With that said, I'd like now to hand the call to Ray Stachowiak, Executive Chairman. Ray, please go ahead.

Ray Stachowiak

executive
#2

Thanks, Kirin. Hello, everyone, and good afternoon. We appreciate you being with us on this call to discuss the results of our fiscal year 2024. Before I get into the numbers, I want to take a moment to share some significant news about our leadership. As of today, we've announced that Gary Delanois has been named Chief Executive Officer of American Shared Hospital Services. I'm going to stay deeply engaged with the company and will keep serving in the role of Executive Chairman, where I'll concentrate on strategy and the biggest opportunities for growth. Gary comes to us with a wealth of background in health care operations as well as financial management. I have great confidence that he can steer AMS through the next stage of growth and innovation. I'll start things off with a few comments, and then I'll pass the call to Gary for more specifics, after which Scott Frech, our CFO, will walk through the financial review of our fiscal year results. Once our prepared remarks are finished, we'll take your questions. We're delighted to share that we've delivered yet another year of robust top-line growth, powered by our strategic efforts, which include continuing to integrate the Rhode Island acquisition, growing our direct patient services segment, and further international business development. We remain firmly dedicated to operational efficiency and financial discipline as we shift away from a focus on leasing cancer treatment equipment toward a service model that puts patients at the center. Looking at the quarter, we kept up both our sequential and year-over-year momentum, posting yet another quarter of solid revenue growth — up 59% versus a year ago and 30% higher than our previous quarter. This improvement came from the ongoing early gains of the Rhode Island acquisition we completed last May, along with the launch of our new radiation therapy treatment facility in Puebla, Mexico. Our fourth quarter 2024 adjusted EBITDA rose 29% over the fourth quarter of 2023; for fiscal year 2024, revenue reached $28.34 million, which is 32.9% higher than fiscal year 2023. Adjusted EBITDA for fiscal '24 was $8.9 million, up 8.9% year-over-year. On top of that, adjusted EBITDA per share came to $1.38, which gives investors a clearer picture of how our financial performance looks. We'd encourage investors to think about what a reasonable EBITDA multiple might be for our enterprise value, considering how recurring and growing our revenues are, our expanding international footprint, and the strategic initiatives we currently have underway. We think now is a great moment for investors to keep a close eye on our company as we carry out our growth strategy and strive to increase shareholder value. Before I turn things over to Gary, I also want to point out our solid balance sheet, strong business development pipeline, and the exciting strategic growth opportunities that fuel our enthusiasm and confidence in where our company is headed over the long term. With that, I'll pass the call to Gary, our new CEO, for more details. Gary?

Gary Delanois

executive
#3

Thank you, Ray, and hello to everyone this afternoon. It's a thrill to step into the CEO position and to assist in guiding our talented leadership group and the organization toward its next stage of expansion. I'll now share a few further specifics regarding our financial results along with our strategic plans. We're enthusiastic about the momentum we've observed across the whole business, which stems directly from our recent purchase of the 3 Rhode Island cancer treatment centers along with our new 1 in Puebla, Mexico. At those Rhode Island facilities, we've put money into CapEx, upgrading the CT simulators employed during treatment planning, and we've also introduced software improvements aimed at boosting efficiency and enhancing patient care. On top of that, we achieved meaningful headway in fine-tuning our staffing expenses, which will strengthen profitability over the long run. To be specific, our professional services agreement with Brown University Health System — the biggest health system in Rhode Island when it comes to radiation oncologists — provides staffing for our 3 centers, which are now completely up and running. That arrangement simplifies how we recruit physicians and enhances what we can offer patients. I'm certain that once every center is fully staffed, we'll start witnessing treatment volume increases at each location, along with stronger physician involvement in the health care community. In addition, we placed our linear accelerators under service and maintenance contracts, which boosts their reliability and delivers higher uptime for superior patient service. The team also keeps concentrating on bolstering our radiation therapy equipment leasing segment by collaborating closely with our health system clients to build greater community awareness among referring physicians, so as to drive more usage of their Gamma Knife systems, the gold standard for stereotactic radiosurgery. Our international business segment likewise offers a substantial growth opportunity, and we anticipate sustained momentum there. As a reminder, we operate the only Gamma Knife centers in Peru and Ecuador; now, with our third international center in Puebla, Mexico, we're treating cancer patients across a full range of cancer diagnoses using the most advanced radiation therapy treatment capabilities available in our catchment area. During fiscal year 2024, we also set up our fourth international center by signing a joint venture agreement for a Gamma Knife center in Guadalajara, Mexico. Looking ahead over the coming months and years, we anticipate stronger international growth driven by additional treatment volumes in Ecuador, solid volume from our newly upgraded center in Peru, and from our 2 new centers in Guadalajara and Puebla, Mexico. We're also continuing to widen our business footprint in Rhode Island. The first of these expansion initiatives was the acquisition of a 60% majority interest in the 3 radiation therapy treatment centers in Rhode Island, which closed this past May. We've launched our very first cancer treatment facilities offering direct patient services within the United States; this fresh business segment plainly showcases how effective our expansion approach is and shows once more that we can work alongside health systems — specifically Care New England and Prospect CharterCARE, which rank as Rhode Island's second and third biggest health systems. Our second move involves the Certificate of Need, also called CON, which we received to construct and run a fourth radiation therapy site located in Bristol, Rhode Island. Then the third effort concerns the CON we formally secured only this past December to construct and run Rhode Island's very first proton beam radiation therapy facility, something that unmistakably proves — stands for yet another major avenue for growth. We're eager to share news about further advancements regarding these possibilities when the appropriate time comes. To wrap up, I want to restate how firmly confident we are in our broader business approach, and I feel tremendous enthusiasm and privilege at collaborating closely with our capable leadership group to steer this company ahead toward sustained revenue and profitability increases across the long run. Having said that, I'll hand things over to Scott so he can walk us through the financials.

Frech Scott

executive
#4

Thanks, Gary, and hello everyone this afternoon. My plan is to begin by going over how we did financially across all of fiscal year 2024, and after that I'll cover the results for the fourth quarter of 2024. When it comes to the fiscal year that closed on December 31, 2024, our total revenue climbed 33%, reaching $28.3 million, up from $21.3 million during fiscal year 2023. The direct patient services portion of our business brought in $12.6 million during fiscal year 2024, versus $3.4 million in fiscal year 2023, which works out to a 253% jump. A big chunk of that growth was driven by us acquiring the radiation therapy business in Rhode Island, along with a 20.5% increase in revenue from Peru and Ecuador, plus the launch of our Puebla, Mexico operations in the third quarter of 2024. Turning to equipment leasing, revenue there declined by $15.6 million, compared with $17.8 million in fiscal 2023. Gamma Knife revenue was down 11.6%, coming in at $9.7 million for fiscal 2024 versus $11 million in fiscal 2023. We did 1,084 Gamma Knife procedures during 2024, a 9.3% decrease from the 1,195 procedures we performed in 2023. That decline happened because 2 contracts came to an end in 2023 and another 1 lapsed in 2024. Proton beam radiation therapy, which we also refer to as PBRT, saw revenue fall 1.8%, coming in at $10 million in fiscal year 2024 versus $10.1 million in fiscal year 2023. We delivered 5,139 total proton therapy fractions in 2024, a 4.3% decline from the 5,369 fractions delivered in 2023. Hurricanes in the state of Florida were the main cause of that decrease, since they hurt volumes, and we also had the usual cyclical ups and downs. Our gross margin for fiscal year 2024 came to $9.2 million, compared with $9.3 million in fiscal year 2023. Higher operational costs, increased spending on staffing, and technology infrastructure investments designed to fuel growth initiatives all contributed to the lower gross margin and percentages, compounded by a decline in Gamma Knife treatment volumes and strong expansion in our patient services segment, which operates at a lower gross margin. Excluding impairment, operating income for the full year 2024 came in at a gain of $279,000, compared to $1.2 million in fiscal year 2023. For fiscal year 2024, net income attributable to American Shared Hospital Services climbed 258% to $2.2 million, or $0.33 per diluted share, up from $610,000, or $0.10 per diluted share, in fiscal year 2023. The primary driver of that substantial increase was the bargain purchase gain associated with the Rhode Island acquisition, along with positive net income contributions from the Rhode Island centers we recently acquired, plus enhanced operational efficiencies across both our domestic and international business segments. Our non-GAAP financial measure, adjusted EBITDA, rose 8.5% to $8.9 million for fiscal year 2024, up from $8.2 million in fiscal year 2023. Now I'll walk through the results for the fourth quarter, which concluded on December 31, 2024. Total revenue climbed 59.2% to $9.1 million, versus $5.7 million during the same period in 2023, fueled by the Rhode Island acquisition that was completed this past May, as well as the new facility located in Puebla, Mexico. Direct patient services revenue came in at $4.8 million, which represents a 420% jump over Q4 2023. That big gain came mainly from buying the Rhode Island radiation therapy centers and getting the Puebla, Mexico facility up and running. Leasing segment revenue fell $4.1 million, down from $4.8 million in Q4 of 2023. The main reason for that drop was weaker Gamma Knife volumes, caused by 2 contracts running out during the second and third quarters of 2023, plus a third contract that expired in the fourth quarter of 2024. Gamma Knife revenue dropped 2.2% to $2.6 million. Gamma Knife procedures came to 253, which is 8.7% below the 277 procedures recorded in Q4 of 2023. During the fourth quarter, revenue from Florida proton beam therapy fell 16%, coming in at $2.6 million. That compares with $3.1 million in Q4 of 2023. On the fractions side, proton therapy hit 1,471, which represents a 39% drop from the 2,396 fractions recorded a year earlier. Gross margin for Q4 of 2024 came to $3.2 million, up against $2.8 million for the same period last year. The decline in that percentage was driven primarily by lower Gamma Knife treatment volumes along with growth in the direct patient services segment, a business that typically generates a lower gross margin. Selling and administrative expenses were down marginally, landing at $1.7 million versus $1.8 million in Q4 of 2023. Interest expense came to $429,000 in Q4 of 2024, compared with $287,000 a year earlier. Looking at the fourth quarter of 2024, we posted an operating loss of $1.8 million. In the fourth quarter of 2023, by contrast, we had operating income of $407,000. The swing is attributable to a write-down on impaired assets along with removal costs, both of which sit in the leasing segment. Turning to taxes, income tax expense came to $71,000 in Q4 2024, whereas the same quarter last year showed $338,000. As for the bottom line, net loss attributable to American Shared Hospital Services totaled $1.3 million in Q4 2024, which works out to $0.20 per share. A year earlier, in Q4 of 2023, we reported net income of $415,000, or $0.06 per share. During Q4 2024, we saw contributions from fresh business development ventures within the direct patient care sector, alongside higher reserves tied to impaired assets and removal expenses totaling $2.9 million in the leasing division. For the fourth quarter of 2024, adjusted EBITDA—a metric not based on GAAP—climbed 29%, reaching $3.5 million, up from $2.7 million during the same quarter in 2023. Thanks to our balance sheet, we ended the year financially solid. As of December 31, 2024, our cash and cash equivalents, which include restricted cash, stood at $11.3 million, down from $13.8 million on December 31, 2023. Shareholders' equity, once you exclude noncontrolling interest in subsidiaries, came to $25.2 million—equivalent to $3.92 for each outstanding share—versus $22.6 million, or $3.59 per outstanding share, as of December 31, 2023. On a fully diluted basis, the weighted average count of common shares outstanding came to 6,542,000 in Q4, compared with 6,552,000 in the fourth quarter of 2023. That wraps up the formal portion of what we came to present. Thanks once more for being with us today. We look forward to updating everyone on our progress in the quarters ahead. Right now, we'll turn the call back to the operator, and following that, we'll open the line for your questions.

Marla Marin

analyst
#5

So, regarding Rhode Island — you've discussed a great deal of expansion there in terms of your footprint. Clearly, that's a major contributor to the revenue growth in 2024. You brought up during the call — Gary addressed it, I believe, in his prepared remarks — the arrangement with Brown University and how it will probably speed up the hiring of medical professionals. Can you think of or mention any additional advantages that come from operating — from growing your presence in that state? And the facilities you're considering, the new ones, the fourth radiation treatment center, the proton beam center — are they near enough to the 3 current facilities for there to be any sort of economies we could discuss?

Ray Stachowiak

executive
#6

Marla, thank you very much for your question. Excellent question, quite insightful. That relationship will yield synergies. Rhode Island is a fairly small state. The 3 biggest health care providers there — Brown University Health is one, and we've just formed this partnership for their delivery of professional services. Care New England, the second largest health care system, holds a 20% equity stake in our 3 radiation therapy centers. And the third largest health care system, Charter — Prospect CharterCARE, likewise holds a 20% equity stake in our 3 radiation therapy centers; and synergies will emerge from every one of those relationships, which will further the delivery of cancer care across the state and will serve as, I'd say, a key focus of that effort.

Ray Stachowiak

executive
#7

I appreciate that, Betsy. And I want to thank all of you for being here with us today. American Shared Hospital Services finds itself at a defining juncture. There's considerable momentum propelling the growth plan we've put in place. Through the acquisition in Rhode Island, we've done more than widen our geographic reach — it gave us our very first business delivering direct patient services inside the United States, which stands as a major milestone for this company. Looking beyond our borders, moving into Mexico, together with ongoing expansion in Peru and Ecuador, makes us even stronger as a frontrunner in specialized radiation therapy services. We understand that pursuing growth brings difficulties along with it. We're ready to handle the intricate challenges of an industry that keeps shifting. By recently broadening our senior leadership team, improving what our equipment portfolio offers, and gaining operational efficiencies, we'll boost both the quality and the accessibility of what we provide. On top of that, securing CON approval in Rhode Island for a fourth radiation therapy center, plus our CON to build and run what's expected to be Rhode Island's first and only proton beam therapy facility, opens up yet another significant long-range chance to expand. Our confidence rests in our strategy and in what our team can deliver. We're eager to share updates on the progress we keep making as we pursue sustainable growth and lasting success. Should anything be unclear, please get in touch. We're always happy to talk. Once more, thank you for your interest in American Shared Hospital Services. Enjoy the remainder of your day and the remainder of your week. Thank you, and goodbye.

Operator

operator
#8

That brings us to the end of this call. We appreciate your joining us for today's presentation. You're welcome to log off at this point.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete American Shared Hospital Services transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

For developers and AI pipelines

Programmatic access to American Shared Hospital Services earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in American Shared Hospital Services or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.